Payout ratio versus pre-lease FCF is suppressed because the source-backed cash-dividend bridge is unavailable.

Operating cash flow dropped 56.1% to NZ$5.5m even though revenue fell only 4.1% to NZ$94.4m, which means the cash result deteriorated several times faster than the top line.

Headline earnings followed the same direction but with sharper operating gearing: EBITDA fell 28.1% to NZ$11.5m, PBT fell 35.9% to NZ$8.2m, and NPAT fell 37.2% to NZ$5.9m. The PBT–NPAT growth gap is only 1.3pp, so tax (28.1% effective rate, up from 26.5%) is not distorting the read.

Capex stepped up roughly eight-fold to NZ$2.8m (3.0% of revenue, versus 0.4% prior), pre-lease free cash flow collapsed to NZ$2.7m from NZ$12.1m, and the interim dividend was held flat at 3.0cps.

The maintained 3.0cps interim costs roughly 150% of current-half NPAT and 330.3% of pre-lease free cash flow, versus 75% of NPAT and 58% of FCF in the prior comparable. Cash on hand fell to NZ$0.1m from NZ$1.8m and gross borrowings rose to NZ$6.0m, so the payout is currently being funded from the balance sheet rather than from in-period cash generation. This matters because the board has chosen to signal payout continuity at a point when earnings, cash and capex are all moving the wrong way simultaneously.

Operating gearing turned hard despite a better gross margin. Gross margin actually expanded 120bps to 49.3%, yet EBITDA fell 28.1% on revenue down only 4.1%. That means costs below the gross line — fulfilment, marketing, overhead — grew materially in absolute terms against a shrinking sales base. The favourable gross-margin headline obscures a deteriorating fixed-cost absorption story.

Capex intensity is no longer trivial. A jump from NZ$0.4m to NZ$2.8m (including NZ$1.3m software development) is the single biggest swing factor in the FCF bridge. Whether this is a one-off platform build or a new run-rate determines whether FCF normalises in H2 or whether the dividend remains structurally uncovered.

Shape context shows HY has historically delivered ~50.8% of full-year revenue and ~47.2% of full-year NPAT, so the business is mildly second-half weighted on profit. Annualising the current half implies roughly NZ$188.8m of revenue, about 2.6% below FY22's NZ$194.0m, and HY22 was flagged by management as a record half lapped against the 2020 lockdown spike — meaning the prior comparable was itself an elevated base.

The gap that matters is between reported earnings durability and cash. If H2 simply repeats H1 cash conversion at 47.7%, full-year OCF would land materially below FY22's NZ$29.5m and the dividend run-rate cannot be funded from operations.

No non-recurring items are disclosed, tax is within Annolyse's historical range at 28.1%, and gross margin actually improved. The earnings decline therefore looks like genuine operating deleverage on a 4.1% revenue contraction, not an accounting artefact.

The cash result is a different question. Three things moved against OCF simultaneously: lower earnings, a NZ$2.7m operating working-capital build (upper edge of the supplied historical range, versus a 3-period mean of NZ$0.7m), and a step-up in capex. Debtor days remain very short at 0.9 days (below Annolyse's historical range), so the working-capital absorption sits in inventories and payables timing rather than receivables stretching. Net debt/EBITDA is still only 0.51x — comfortably inside the historical 0.77x-1.91x range — so there is balance-sheet capacity, but leverage has moved from a near-zero base and ROE has fallen to 9.3% from 14.8%.

This briefing cannot assess management's outlook commentary on H2 trading, customer numbers, or capital allocation intent beyond what the canonical metrics imply.